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The classification of receptors for adenosine, ATP and ADP (collectively called 
purinoceptors) has seen a number of developments in the past three years. The important 
division of receptors into two major classes1 (1) adenosine (P1) receptors and (2) P2 
purinoceptors, first suggested by Burnstock in 1978 (Ref.2), has been an abiding one that 
has set the stage for further subdivision of P2 purinoceptors into P2X and P2Y subtypes on 
the basis of pharmacological properties3. Later, Dubyak4 summarized the evidence that ATP 
worked through two different transduction mechanisms: intrinsic ion channels and G 
protein-coupled receptors. This information, coupled with the cloning of purinoceptors in 
1993/94, led Abbracchio and Burnstock5 to propose that purinoceptors should be classified 
in two families: G protein-coupled receptors termed P2Y purinoceptors, and intrinsic ion 
channels termed P2X purinoceptors. Developments in recent years have borne out these 
expectations and a revised nomenclature, essentially adopting the Abbracchio and Burnstock 
proposal, can now be proposed.
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The existence of four separate adenosine receptors is well established6. In conformity with 
the International Union of Pharmacology Committee on Receptor Nomenclature and Drug 
Classification (NC-IUPHAR) recommendations, the two A2 receptors are now named A2A 
and A2B (rather than A2a and A2b). Although there are reports of binding sites that suggest 
the existence of additional subtypes7-11, no evidence for new A2 receptors has evolved from 
the extensive cloning efforts of several laboratories. Indeed at least one of these sites 
(denoted A4 by the authors) may represent binding to a state of the A2A receptor12, and a 
similar explanation may apply to the other putative receptor binding sites. If additional 
adenosine receptors are cloned and shown to be structurally different from the four known 
receptors and if, in addition, a distinct pharmacological profile (both binding and functional 
response) is established they are to be named A4, A5, etc. Until such time, naming of 
putative binding sites is strongly discouraged.
P2 receptors
Although indicating a preference for the use of P2X, P2Y classification, the first NC-
IUPHAR subcommittee for Purinoceptors report1 provisionally divided P2 purinoceptors 
into six subforms P2X, P2Y, P2U, P2t, P2z and P2d. This classification was, at the time, 
pointed out to be unsatisfactory and in need of revision for the following two reasons: (1) 
there may be receptors that preferentially bind pyrimidine rather than purine nucleotides, 
and (2) the nomenclature did not conform with NC-IUPHAR classification principles (Box 
1) – the eventual cloning of P2 receptors would provide a basis for a more logical 
classification scheme. Both of these contentions have been borne out. In particular, there is 
now a strong structural basis for a nomenclature scheme.
As described in detail in two recent articles, one in this issue of TiPS (Communi and 
Boeynaems), very compelling evidence now exists for receptors that are structurally similar 
to receptors for ATP, but strongly prefer, or even are selective for, UTP or UDP (Refs 13, 
14). Therefore, we suggest that the family of receptors be named P2 receptors rather than P2 
purinoceptors. A P2 receptor is now defined as a receptor for a purine or pyrimidine 
nucleotide (or dinucleotide). One important corollary to this general nomenclature is that 
there is little room for potential P3 or P4 receptors. The name P3 receptor (see Ref. 15) was 
introduced on the basis of the original definition of P1 and P2 receptors and included the 
block of responses by methylxanthines as a discriminating criterion16. In the proposed, new 
nomenclature, this criterion is dropped. Any unambiguously identified receptor for adenine 
nucleotides at which methylxanthines also bind and act as antagonists will in future be 
incorporated into the P2X/P2Y scheme. The name P4 receptor, proposed for receptors for 
adenine dinucleotides17, is no longer useful as, according to the newly advocated 
nomenclature, such receptors would be likely to fit into the P2Y array of receptors.
Rapid and spectacular advances have occurred in the area of the ionotropic P2X receptors 
(intrinsic ion channels; see Table 1). Perhaps the most surprising finding is that the ATP-
activated large conductance pore, tentatively named P2Z, has been shown to be a member of 
the family (P2X7)18. As is the case for other ionotropic receptors (nicotinic, GABAA 
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receptors, etc.), functional P2X receptors may be composed of several interacting subunits, 
which need not be the same. This can lead to the potential generation of a large number of 
operationally (and perhaps pharmacologically) distinct functional entities. Indeed, it has 
been found that simultaneous tranfection of the P2X2 and P2X3 subforms leads to the 
expression of a receptor that shows properties that are typical of neither subform (see Table 
1). The use of the presently available pharmacological tools alone for characterization of 
receptors has presented a number of problems. We are of the opinion that for the time being 
the nomenclature should apply predominantly structural criteria. As new, selective agonists 
and antagonists become available however, the situation is expected to improve.
Many G protein-coupled P2 receptors now have been cloned (see Table 2). Nomenclature 
for these cloned receptors is still very much under discussion but, for the time being we 
suggest the receptor putatively named p2y3 (Ref. 19) is given in lower case letters because it 
was cloned from chick. The reason for this caution is because of a precedence for the 
occurrence of major differences between mammalian and avian G protein-coupled receptors 
from, for example, β-adrenoceptors. Whereas there is considerable homology in the case of 
β2-adrenoceptors (about 90%), the homology in the case of the β1-adrenoceptor is only about 
50%. Moreover, a β-receptor has been cloned from the turkey, for which no mammalian 
species homologue has been identified despite wide-ranging efforts to do so. In the case of 
the p2y5 (Ref. 20) and P2Y7 receptors21, where the sequence homology of the two proteins 
to previously identified members of the P2Y receptor family is low, we anticipate further 
findings in this area (Table 2).
Box 1
Some open questions
Debate about the classification of receptors from non-mammalian species still continues 
but the official recommendations from the International Union of Pharmacology 
Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) state that: 
“Mammalian receptor systems are the basis of IUPHAR classifications. The 
nomenclature may extend to other vertebrate species provided it does not compromise the 
mammalian classification. Evolutionary changes may be so great that invertebrate 
receptors are difficult to classify within mammalian-based nomenclature.”
Research on human receptors may lag behind that on non-human receptors, for reasons of 
ethical considerations in obtaining human foetal material, and because of the complexity 
of human systems. The NC-IUPHAR recognizes that the discovery process is often 
simplified by using non-mammalian organisms. The tremendous importance of genes 
identified in Drosophila, C. elegans or in yeast strains is a case in point.
It must be pointed out that the ADP receptor in platelets, which was pharmacologically 
defined years ago (see Ref. 2), has not yet been cloned. In such a case NC-IUPHAR 
recommends that the name be given in italics. In order not to preempt the efforts of cloning, 
we recommend the term P2YADP rather than, e.g. P2Y8 or P2Y9. The recently reported p2y3 
receptor from the chick19 shows a preference for ADP, but is clearly different from the 
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platelet ADP receptor. It is possible, but far from certain, that a mammalian homologue of 
the chick p2y3 receptor would be the long sought-after receptor.
Since the nomenclature for P2 receptors is based largely on structure numerous questions 
arise. For example, how should a pharmacologist working in isolated tissues name a new 
receptor if it responds to UTP in preference to ATP, particularly if it is not clear what 
molecular type of receptor is involved? In such a situation, the term UTP- (or UDP-) 
preferring P2(Y) receptor is recommended (the letter Y included only in cases where there is 
evidence that the receptor is indeed of the Y type, i.e. G protein coupled). The more 
descriptive term should be used since the observed response could be due to several 
different cloned receptors, alone or in combination.
For future developments, the reader is refererred to the Web site maintained by G. 
Burnstock and B. King, who have done the field a great service by providing a ready access 
to the latest discoveries on P2 receptors49. (http://ylem.anat.ucl.ac.uk/research/burnstock/
nomenclature.html see also http://mgddk1.niddk.nih.gov:8000/nomenclature.html.)
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Species (Accession number) Pharmacological characteristicsf,l,m
Response to
α,β-Me-ATP
Desensitization Block by PPADS
and suramin
Refs
P2X1 Rat (X80477), Human (X83688),
Mouse (X84896)
Yes Yes Yes 22,23
P2X2 Rat (U14414) Short form (L43511) No No Yes 24,25
P2X3 Rat (X90651, X91167) Yes Yes Yes 26,27
P2X2 and P2X3 Yes No Yes
P2X4 Rat (X91200, X87763, U32497,
X93565, U47031)
No No No* 28 – 32
P2X5 Rat (X92069) No No Yes 33
P2X6 Rat (X90270) No No No 33




hP2X4 receptor is blocked by PPADS and suramin [Soto, F., Garcie-Cuyman, M. and Stuhmer, W. (1996) Neurosci. Abstr. 137.10]
**
It is possible that there may be more than one form of the “P2Z” receptor.
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Table 2
P2Y receptors
P2Y subtypes Species Accession number Refs











Mouse L1 4751 43
p2y3 (chick) Chick X98283 19
P2Y4 Human X91852, U40223 44,45







P2Y7* Human U41070 21
p2y (novel receptor in embryonic
nervous system)
Xenopus 48
P2ZADP Functionally defined ADP receptor (e.g. platelets). Not cloned.
P2YAp4A Functionally defined adenine nucleotide receptor. Not cloned.
Note that in accordance with the general IUPHAR rules, the names of receptor species for which there is good pharmacological evidence, but 
which have not been cloned, are given in italics. Conversely, the names of receptors for which there is only data from cloning experiments and for 
which there is no evidence of a functional role are given in lower case letters.
*
The only published data on this receptor suggests that this gene product fulfils the criteria to name this receptor. References:
a
Leon et al. 1995. Direct submission to Genbank,
b
Seye et al. 1996. Direct submission to Genbank.
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